Ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. In particular, advanced ovarian clear cell carcinoma with wildtype p53 has a poor prognosis, drug resistance, metastasis and recurrence. The research team of Dr. Wendy W. Hwang-Verslues at Genomics Research Center found that MEX3A facilitates p53 degradation to drive ovarian cancer growth by circumventing p53-mediated ferroptosis. These findings suggest that targeting MEX3A can be a potential strategy for treating of ovarian cancer expressing wildtype p53 and were published in Cancer Research.
For further information